Pliant assembles outside expert panel to review bexotegrast trial after DSMB pause recommendation

PLIANT THERAPEUTICS, INC.

DSMB recommended pause of enrollment and dosing in BEACON-IPF Phase 2b trial of bexotegrast in IPF.
Company initiated assembly of outside expert panel (pulmonary experts and biostatisticians) to review unblinded data.
Company could not determine DSMB rationale from blinded data; panel will provide independent recommendation then join expanded DSMB.
Process expected to conclude in 2-4 weeks; company remains blinded to maintain trial's potential as registrational.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.